Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Patent metadata

Field	Value
Publication number	US-11197836-B2
Application number	US-201514934275-A
Country	US
Kind code	B2
Filing date	Nov 6, 2015
Priority date	Jun 17, 2005
Publication date	Dec 14, 2021
Grant date	Dec 14, 2021

Abstract

Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

First claim

What is claimed is:

1. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia, wherein the preparation is in a liquid form, and wherein the delivery vehicle comprises an aqueous alcohol mixture.

2. The method of claim 1 , wherein the vasoconstrictor comprises epinephrine.

3. The method of claim 1 , wherein the vasoconstrictor comprises phenylephrine.

4. The method of claim 1 , wherein the vasoconstrictor comprises norepinephrine.

5. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia, wherein the delivery vehicle comprises an alcohol.

6. The method of claim 1 , wherein the patient is a patient treated or to be treated with cyclophosphamide.

7. The method of claim 1 , wherein the delivery vehicle comprises at least 10% alcohol.

8. The method of claim 1 , wherein the delivery vehicle comprises at least 55% alcohol.

9. The method of claim 1 , wherein the epinephrine, the phenylephrine, the norepinephrine, or the combination thereof comprises an epinephrine salt, a phenylephrine salt, a norepinephrine salt, or a combination thereof.

10. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia.

11. The method of claim 10 , wherein the epinephrine, the phenylephrine, the norepinephrine, or the combination thereof comprises an epinephrine salt, a phenylephrine salt, a norepinephrine salt, or a combination thereof.

12. The method of claim 10 , wherein the vasoconstrictor comprises epinephrine.

13. The method of claim 10 , wherein the vasoconstrictor comprises phenylephrine.

14. The method of claim 10 , wherein the vasoconstrictor comprises norepinephrine.

15. The method of claim 10 , wherein the patient is a patient treated or to be treated with cyclophosphamide.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Fahl William E
• Ruoho Arnold E
• Mehta Minesh

Classifications

• A61K31/137 Primary

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title